MX2021004940A - Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos. - Google Patents

Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.

Info

Publication number
MX2021004940A
MX2021004940A MX2021004940A MX2021004940A MX2021004940A MX 2021004940 A MX2021004940 A MX 2021004940A MX 2021004940 A MX2021004940 A MX 2021004940A MX 2021004940 A MX2021004940 A MX 2021004940A MX 2021004940 A MX2021004940 A MX 2021004940A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
sulfonamide derivatives
pyridinyl sulfonamide
pyridinyl
sup
Prior art date
Application number
MX2021004940A
Other languages
English (en)
Inventor
Stefan Peters
Andreas Blum
Joerg P Hehn
Oliver Hucke
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2021004940A publication Critical patent/MX2021004940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

La invención se refiere a nuevos derivados de piridinil sulfonamida de la Fórmula (I) (ver Fórmula) en donde R1, A y n son como se definieron en la descripción y en las reivindicaciones, a su uso como medicamentos, a métodos para su uso terapéutico y a composiciones farmacéuticas que los contienen.
MX2021004940A 2018-10-29 2019-10-24 Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos. MX2021004940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18203196 2018-10-29
PCT/EP2019/078992 WO2020089026A1 (en) 2018-10-29 2019-10-24 Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2021004940A true MX2021004940A (es) 2021-06-08

Family

ID=64082994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004940A MX2021004940A (es) 2018-10-29 2019-10-24 Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.

Country Status (29)

Country Link
US (1) US20210361637A1 (es)
EP (1) EP3873600B9 (es)
JP (1) JP7317109B2 (es)
KR (1) KR20210084537A (es)
CN (1) CN112955215A (es)
AU (1) AU2019373306A1 (es)
BR (1) BR112021004635A2 (es)
CA (1) CA3112510A1 (es)
CL (1) CL2021000839A1 (es)
CO (1) CO2021005509A2 (es)
CR (1) CR20210216A (es)
DK (1) DK3873600T5 (es)
DO (1) DOP2021000068A (es)
EA (1) EA202191114A1 (es)
EC (1) ECSP21030482A (es)
FI (1) FI3873600T3 (es)
HR (1) HRP20231608T1 (es)
IL (1) IL282428A (es)
LT (1) LT3873600T (es)
MA (1) MA54051A (es)
MX (1) MX2021004940A (es)
PE (1) PE20211467A1 (es)
PL (1) PL3873600T3 (es)
PT (1) PT3873600T (es)
RS (1) RS64963B1 (es)
SA (1) SA521421755B1 (es)
SG (1) SG11202102440SA (es)
SI (1) SI3873600T1 (es)
WO (1) WO2020089026A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112955214A (zh) * 2018-10-29 2021-06-11 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
JP2022547719A (ja) 2019-09-13 2022-11-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニストおよびその使用
CN114621189B (zh) * 2020-12-14 2024-01-02 上海拓界生物医药科技有限公司 一种内酰胺类衍生物及其用途
CN114621243B (zh) * 2020-12-14 2024-03-01 上海拓界生物医药科技有限公司 一种磺酰胺类衍生物及其用途
CN114621190B (zh) * 2020-12-14 2023-12-05 上海拓界生物医药科技有限公司 一种烯丙基胺类衍生物及其用途
EP4301756A1 (en) 2021-03-05 2024-01-10 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335975A (en) 1996-12-19 2000-11-24 Hoechst Marion Roussel Inc Heterocyclic substituted pyrrolidine amide derivatives useful in treating respiratory diseases
CL2007003580A1 (es) 2006-12-11 2009-03-27 Boehringer Ingelheim Int Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes.
US9192617B2 (en) * 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SI2844637T1 (en) 2012-05-02 2018-07-31 Boehringer Ingelheim International Gmbh Substituted 3-haloaliline SSAO inhibitors and their use
PL3455216T3 (pl) * 2016-05-12 2021-05-17 Boehringer Ingelheim International Gmbh Pochodne pirydynylowe, kompozycje farmaceutyczne i ich zastosowania jako inhibitory aoc3
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
CN112955214A (zh) * 2018-10-29 2021-06-11 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途

Also Published As

Publication number Publication date
CN112955215A (zh) 2021-06-11
FI3873600T3 (fi) 2023-12-07
EP3873600A1 (en) 2021-09-08
HRP20231608T1 (hr) 2024-03-15
BR112021004635A2 (pt) 2021-05-25
CA3112510A1 (en) 2020-05-07
CR20210216A (es) 2021-06-24
JP2022506198A (ja) 2022-01-17
IL282428A (en) 2021-06-30
DK3873600T3 (da) 2024-01-02
CO2021005509A2 (es) 2021-05-10
RS64963B1 (sr) 2024-01-31
PE20211467A1 (es) 2021-08-05
DOP2021000068A (es) 2021-06-30
AU2019373306A1 (en) 2021-04-08
KR20210084537A (ko) 2021-07-07
LT3873600T (lt) 2023-12-27
CL2021000839A1 (es) 2021-10-15
ECSP21030482A (es) 2021-05-31
PT3873600T (pt) 2023-12-15
PL3873600T3 (pl) 2024-03-11
JP7317109B2 (ja) 2023-07-28
WO2020089026A1 (en) 2020-05-07
EP3873600B9 (en) 2024-02-14
EA202191114A1 (ru) 2021-09-22
SG11202102440SA (en) 2021-04-29
US20210361637A1 (en) 2021-11-25
MA54051A (fr) 2022-02-09
SA521421755B1 (ar) 2022-11-08
SI3873600T1 (sl) 2024-02-29
DK3873600T5 (da) 2024-03-18
EP3873600B1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
MX2021004940A (es) Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
TN2018000410A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2021004000A (es) Derivados de piperidina.
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
CR20220014A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
PH12018502376B1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
EA202092955A1 (ru) Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза
PH12021550788A1 (en) New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
ZA202203108B (en) Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
ZA202203106B (en) Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
MX2020014327A (es) Nuevos derivados de amino-pirimidonilo un proceso para su preparacion y composiciones farmaceuticas que los contienen.
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
WO2018067762A3 (en) Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections